Learn About Spinal Muscular Atrophy Type 2

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Spinal Muscular Atrophy Type 2 Local Doctors?
EM
Eugenio M. Mercuri
Elite
Highly rated in
40
conditions

Università Cattolica Del Sacro Cuore

Rome, IT 

Eugenio Mercuri is in Rome, Italy. Mercuri is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 2. He is also highly rated in 40 other conditions, according to our data. His top areas of expertise are Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Primary Lateral Sclerosis.

View Profile
MP
Marika A. Pane
Elite
Highly rated in
16
conditions

Università Cattolica Del Sacro Cuore

Rome, IT 00168

Marika Pane is in Rome, Italy. Pane is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 2. She is also highly rated in 16 other conditions, according to our data. Her top areas of expertise are Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 1, and Becker Muscular Dystrophy.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
GC
Giorgia Coratti
Elite
Highly rated in
7
conditions

Università Cattolica Del Sacro Cuore

Rome, IT 

Giorgia Coratti is in Rome, Italy. Coratti is rated as an Elite expert by MediFind in the treatment of Spinal Muscular Atrophy Type 2. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy, and Spinal Muscular Atrophy Type 1.

View Profile
View All Doctors
What are the Latest Advances for Spinal Muscular Atrophy Type 2?
A Case Report of Systemic Intoxication Following Onabotulinum Toxin A Injections Into the Salivary Glands in a Patient With Spinal Muscular Atrophy Type 1.
Condition: Spinal Muscular Atrophy (SMA) Type 1/Sialorrhea/Systemic Intoxication
Journal: Pediatric neurology
Treatment Used: Botulinum Toxin (BTX) Injections into the Salivary Glands
Number of Patients: 1
Published: February 26, 2022
View publication
Summary: A Case Report of Systemic Intoxication Following Onabotulinum Toxin A Injections Into the Salivary Glands in a Patient With Spinal Muscular Atrophy Type 1.
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Condition: Spinal Muscular Atrophy
Journal: The Lancet. Neurology
Treatment Used: Risdiplam
Number of Patients: 180
Published: December 23, 2021
View publication
Summary: Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Tired of the same old research?
Check Latest Advances
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Condition: Spinal Muscular Atrophy
Journal: Advances in therapy
Treatment Used: Nusinersen
Number of Patients: 23
Published: October 29, 2021
View publication
Summary: Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
View All Latest Advances
What are the latest Spinal Muscular Atrophy Type 2 Clinical Trials?
Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias
Status: Recruiting
Start Date: September 1, 2020
Intervention Type: Other, Diagnostic Test
View Trial
Summary: The aim of this study is to determine the clinical spectrum and natural progression of Spastic Ataxias (SPAX) and related disorders in a prospective multicenter natural history study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the genetic etiology and molecular mechanisms of these diseases.
Match to trials
Find the right clinical trials for you in under a minute
Get started
Biomarker Development for Muscular Dystrophies
Status: Recruiting
Start Date: February 20, 2015
View Trial
Summary: Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystr...
View All Clinical Trials